1. Home
  2. VSTS vs LXEO Comparison

VSTS vs LXEO Comparison

Compare VSTS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$6.92

Market Cap

572.2M

Sector

N/A

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$9.38

Market Cap

663.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
LXEO
Founded
1936
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
572.2M
663.5M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
VSTS
LXEO
Price
$6.92
$9.38
Analyst Decision
Sell
Strong Buy
Analyst Count
4
9
Target Price
$5.95
$18.22
AVG Volume (30 Days)
3.0M
1.2M
Earning Date
12-01-2025
11-05-2025
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,734,839,000.00
N/A
Revenue This Year
$1.47
N/A
Revenue Next Year
$3.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$1.45
52 Week High
$17.83
$10.38

Technical Indicators

Market Signals
Indicator
VSTS
LXEO
Relative Strength Index (RSI) 73.32 53.99
Support Level $5.30 $9.27
Resistance Level $6.73 $10.04
Average True Range (ATR) 0.40 0.63
MACD 0.07 -0.08
Stochastic Oscillator 97.95 59.94

Price Performance

Historical Comparison
VSTS
LXEO

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Share on Social Networks: